PIM 家族在弥漫性大 B 细胞淋巴瘤免疫微环境中的作用及机制。

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.

机构信息

Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China.

出版信息

World J Surg Oncol. 2023 Mar 4;21(1):76. doi: 10.1186/s12957-023-02947-5.

DOI:10.1186/s12957-023-02947-5

PMID:36871027

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9985240/

Abstract

BACKGROUND

Diffuse large B cell lymphoma (DLBCL) is a more common non-Hodgkin lymphoma (NHL). This study aims to explore the prognostic value of PIM kinase family in DLBCL and its relationship with the immune microenvironment, to provide a certain reference for the prognosis and treatment of DLBCL.

METHODS

The prognostic value of PIM kinase family in DLBCL from the data set GSE10846 was verified through survival analysis and cox regression analysis. Mutations in PIM kinase family and its relationship with immune cell infiltration were explored with online cBioPortal, TIMER database, and single-gene GSEA analysis. Finally, the expression of PIM kinase family in tissues from DLBCL clinical samples was validated through immunohistochemical staining.

RESULTS

The proteins of PIM kinase family were highly expressed in DLBCL patients, which are good prognostic factors for DLBCL patients. Then, PIM1-3 proteins were positively correlated with the immune infiltration of B cells, whose types of mutations also showed different degrees of correlation with B cells. PIM kinase family proteins also showed a high correlation with PDL1. In addition, PIM kinase family was also associated with the commonly mutated genes in DLBCL, such as MYD88, MYC, and BTK.

CONCLUSION

PIM kinase family may be a potential therapeutic target for DLBCL patients.

摘要

背景

弥漫性大 B 细胞淋巴瘤（DLBCL）是一种较为常见的非霍奇金淋巴瘤（NHL）。本研究旨在探讨 PIM 激酶家族在 DLBCL 中的预后价值及其与免疫微环境的关系，为 DLBCL 的预后和治疗提供一定的参考。

方法

通过生存分析和 COX 回归分析验证了来自数据集 GSE10846 的 PIM 激酶家族在 DLBCL 中的预后价值。通过在线 cBioPortal、TIMER 数据库和单基因 GSEA 分析探索了 PIM 激酶家族的突变及其与免疫细胞浸润的关系。最后，通过免疫组织化学染色验证了 PIM 激酶家族在 DLBCL 临床样本组织中的表达。

结果

PIM 激酶家族的蛋白在 DLBCL 患者中高表达，是 DLBCL 患者的良好预后因素。然后，PIM1-3 蛋白与 B 细胞的免疫浸润呈正相关，其突变类型也与 B 细胞呈不同程度的相关性。PIM 激酶家族蛋白与 PDL1 也呈高度相关性。此外，PIM 激酶家族还与 DLBCL 中常见的突变基因如 MYD88、MYC 和 BTK 相关。